ArticlePulmonary therapy2026
Real-World Effectiveness of Mepolizumab Initiation in Treating Asthma and Concurrent Chronic Obstructive Pulmonary Disease in the US.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMepolizumab reduces exacerbations in patients with asthma but real-world data on its effectiveness in asthma and concurrent chronic obstructive pulmonary disease (COPD) are limited. This study assessed the real-world impact of mepolizumab initiation in patients with asthma and concurrent COPD.
methodsRetrospective, longitudinal analysis from the US Komodo Research claims database (January 2016-June 2023). Eligible patients (aged ≥ 12 years; ≥ 2 mepolizumab claims) had ≥ 1 asthma claim and were categorized as asthma with concurrent COPD (≥ 1 COPD claim) or asthma only. Outcomes assessed in the 12 months post- versus 12 months pre-mepolizumab initiation included annualized exacerbation rates, oral corticosteroid (OCS) dispensing and burst rates, and asthma- and COPD-related healthcare resource utilization (HCRU), and healthcare costs.
resultsA total of 2106 patients had asthma with concurrent COPD; 4674 asthma only. The annualized rate of exacerbations decreased by 50% post- versus pre-mepolizumab in patients with asthma and concurrent COPD {rate ratio [95% confidence interval (CI)]: 0.50 [0.48, 0.53]; P < 0.001}, and by 49% in patients with asthma only [0.51 (0.49, 0.53); P < 0.001]. The relative reduction [rate ratio (95% confidence interval)] in hospitalization-defined exacerbations was 52% [0.48 (0.42, 0.54); P < 0.001] and 41% [0.59 (0.52, 0.67); P < 0.001] in the asthma with concurrent COPD and asthma-only cohorts, respectively. Relative reductions of between 36 and 44% in OCS dispensing and bursts were observed across both cohorts (P < 0.001); relative reductions of 42-49% were observed across both cohorts in HCRU, including in hospitalizations and emergency room visits (P < 0.001). Mean total healthcare costs per patient per year in the asthma with concurrent COPD cohort were $11,770 (30,663) post- versus $23,771 (66,737) pre-mepolizumab initiation, corresponding to a cost difference (95% CI) of $-12,001 (-14,816, -9,186) (P < 0.001).
conclusionIn this analysis of a large US claims database, mepolizumab reduced exacerbations and overall disease burden in patients with asthma and concurrent COPD.
Indexed as
Identifiers
42786303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.